Introduction {#S1}
============

It was recognised over half a century ago that malaria has been a major force for evolutionary selection on the human genome, and that certain haematological disorders have risen to high frequency in malaria-endemic areas because they reduce the risk of death due to malaria.^[@R1]--[@R3]^ Sickle haemoglobin (HbS) and glucose-6-phosphate dehydrogenase (G6PD) deficiency are often-quoted examples of natural selection due to malaria, and many other genetic associations with resistance or susceptibility to malaria have been reported.^[@R2]--[@R9]^. However the current literature contains many conflicting lines of evidence based on relatively small studies that have not been independently replicated.

To address this problem we conducted a large multi-centre case-control study of severe malaria across 12 locations in Burkina Faso, Cameroon, The Gambia, Ghana, Kenya, Malawi, Mali, Nigeria, Tanzania, Vietnam and Papua New Guinea ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The structure of this consortial project has been described elsewhere^[@R10]^ and information about each of the partner studies can be found on the MalariaGEN website (see URLs). We used the World Health Organisation definition of severe malaria which comprises a broad spectrum of life-threatening clinical complications of *Plasmodium falciparum* infection.^[@R11]--[@R15]^ In this report we examine genetic associations with severe malaria in general and with two distinct clinical forms of severe malaria: cerebral malaria with a Blantyre coma score of less than 3; and severe malarial anaemia with a haemoglobin level of less than 5g/dl or a haematocrit of less than 15%.

RESULTS {#S2}
=======

Samples and Clinical Data {#S3}
-------------------------

The first stage of work was to collect standardised clinical data on severe malaria from multiple locations ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). This presents many practical challenges as severe malaria is an acute illness that mainly occurs in resource-poor settings where laboratory facilities are limited and medical records can be unreliable. It was necessary to allow for variations in the design and implementation of the study in different settings, which depended on a range of local circumstances. Investigators at different sites agreed at the outset on principles for sharing data and on standardised clinical definitions, and they also worked together to define best ethical practices across different local settings including the development of guidelines for informed consent.^[@R10],[@R16],[@R17]^ A set of web tools was developed to enable investigators to curate data in their locally used format before transforming it to the standardised format necessary for data from different sites to be merged.

After data curation and quality control (see Online Methods) 11,890 cases of severe malaria and 17,441 controls were included for analysis ([Table 1](#T1){ref-type="table"} and [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Controls were intended to be representative of the populations to which the cases belonged, i.e. a minority of controls may have subsequently gone on to develop severe malaria. [Supplementary Table 4](#SD2){ref-type="supplementary-material"} shows the ethnic composition of cases and controls at each location. A total of 6,283 cases had cerebral malaria or severe malarial anaemia, of which 3,345 had cerebral malaria only, 2,196 had severe malarial anaemia only and 742 had both cerebral malaria and severe malarial anaemia ([Table 1](#T1){ref-type="table"}). A further 5,607 cases did not have cerebral malaria or severe malarial anaemia according to the criteria used here but satisfied the WHO definition of severe malaria which includes a range of other clinical complications, such as acidosis, respiratory distress and hypoglycaemia, which are not explored in detail in the present analysis.^[@R11]^

Most of the cases of severe malaria were young children, with median ages ranging from 1.3 to 3.8 years at different study sites, except in Vietnam where most were young adults with a median age of 29 years. The median age for severe malarial anaemia was 32 months and for cerebral malaria was 62 months ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Cerebral malaria was more common than severe malarial anaemia in The Gambia, Kenya, Malawi and Vietnam, whereas severe malarial anaemia was more common than cerebral malaria in Burkina Faso, Cameroon, Ghana, Mali, Papua New Guinea and Tanzania. It has previously been observed that severe malarial anaemia particularly affects young African children exposed to extremely high levels of malaria transmission, whereas cerebral malaria particularly affects older African children exposed to lower levels of malaria transmission^[@R18],[@R19]^. The mean case fatality rate following treatment was 18% for cerebral malaria, 4% for severe malarial anaemia and 10% for severe malaria overall ([Table 1](#T1){ref-type="table"}).

Genetic loci analysed {#S4}
---------------------

We tested previously reported associations with severe malaria for 55 SNPs in 27 gene regions: *ABO, ADORA2B, ATP2B4, C6, CD36, CD40LG, CR1, DARC, G6PD, GNAS, HBB, ICAM1, IL10, IL13, IL1A, IL1B, IL22, IL4, IRF1, LTA, NOS2, SPTB, TLR1, TLR4, TLR6, TLR9*, and *TNF* (for references see [Supplementary Table 5--7](#SD2){ref-type="supplementary-material"}). Note that this report focuses on SNPs that we were able to genotype reliably using the Sequenom platform, i.e. we do not here consider structural variants such as those responsible for α-thalassaemia. Other SNPs were included for purposes of quality control ([Supplementary Tables 5--7](#SD2){ref-type="supplementary-material"}, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). All SNPs were initially tested for association with severe malaria using a standard logistic regression method and assuming fixed effects across different populations (See Online Methods). We also tested for association with cerebral malaria and severe malarial anaemia individually, and for different models of inheritance. Results for all SNPs are shown in [Supplementary Tables 8--10](#SD2){ref-type="supplementary-material"} and [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}, and below we discuss those SNPs that showed strong evidence of association in the multi-centre analysis.

HBB {#S5}
---

*HBB* encodes β-globin which has three well-known structural variants that have been associated with resistance to malaria: haemoglobin S (HbS), haemoglobin C (HbC) and haemoglobin E (HbE)^[@R2],[@R7]--[@R9]^. The SNP responsible for HbS, rs334, was present at all the African sites with heterozygote frequencies in controls ranging from 0.05 (Malawi) to 0.22 (Nigeria). Heterozygotes had a reduced risk of severe malaria (odds ratio (OR) 0.14, *P* = 1.6 × 10^−225^), cerebral malaria (OR 0.11, *P* = 4.7 × 10^−88^) and severe malarial anaemia (OR 0.11, *P* = 9.3 × 10^−65^) as shown in [Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"} and [Supplementary Table 11](#SD2){ref-type="supplementary-material"}. The SNP responsible for HbC, rs33930165, was present only in West Africa (Burkina Faso, The Gambia, Ghana, Mali, Cameroon and Nigeria) with frequencies of the derived (non-ancestral/non-reference) alleles ranging from 0.01 to 0.15 in controls. The strongest signal of association with severe malaria was seen under an additive genetic model, i.e. the greatest protective effect was seen in homozygotes. As shown in [Table 2](#T2){ref-type="table"}, each copy of the derived allele reduced the risk of severe malaria by 29% (OR 0.71, *P* = 6.9 × 10^−9^), of cerebral malaria by 28% (OR 0.72, *P* = 0.01) and of severe malarial anaemia by 26% (OR 0.74, *P* = 2.1 × 10^−3^). The SNP responsible for HbE, rs33950507, was found at a derived allele frequency of 0.4 in the S'tieng ethnic group in Vietnam but was rare or absent in other ethnic groups, such that the sample was too small to estimate association with severe malaria.

ABO {#S6}
---

*ABO* encodes the glycosyltransferase enzyme which determines ABO blood group. Individuals who are homozygous for a single nucleotide deletion (rs8176719) in *ABO* have an inactive form of the glycosyltransferase and can be classified as blood group O.^[@R20]^ Estimated by this method, the frequency of blood group O in control samples ranged from 0.32 in Papua New Guinea to 0.62 in Nigeria ([Supplementary Table 12](#SD2){ref-type="supplementary-material"}). Combined analysis across all sites showed that blood group O was associated with decreased risk of severe malaria (OR 0.74, *P* = 5.0 × 10^−32^), of cerebral malaria (OR 0.73, *P* = 8.9 × 10^−16^) and of severe malarial anaemia (OR 0.68, *P* = 7.9 × 10^−14^) ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). We also analysed rs8176746, a non-synonymous coding SNP in *ABO* that is in linkage disequilibrium (LD) with rs8176719 and determines the production of B antigens, such that the majority of individuals carrying the derived allele express blood group B.^[@R20]--[@R22]^ The derived allele was associated in a dominant gene model with increased risk of severe malaria (OR=1.25, *P* = 2.0 × 10^−17^) ([Table 2](#T2){ref-type="table"}).

G6PD {#S7}
----

*G6PD* is an X-linked gene encoding glucose-6-phosphate dehydrogenase with many allelic variants^[@R23]^. The major form of G6PD enzyme deficiency in Africa is encoded by the derived allele of rs1050828, commonly known as G6PD+202T.^[@R24]^ Two other SNPs that cause G6PD deficiency are found in The Gambia but are rare in the other populations studied here.^[@R25]^ In this study, the G6PD+202T allele was present at frequencies ranging from 0.03 in Gambia to 0.28 in Nigeria ([Supplementary Table 13](#SD2){ref-type="supplementary-material"}). Aggregated across all African sites, we found an increased risk of severe malarial anaemia in male hemizygotes (OR 1.49, *P* = 3.6 × 10^−5^) and in females homozygotes under a recessive model of association (OR=1.94, *P* = 1.9 × 10^−3^) ([Table 3](#T3){ref-type="table"} and [Supplementary Tables 14, 15](#SD2){ref-type="supplementary-material"}). In contrast, there was a trend towards decreased risk of cerebral malaria in female heterozygotes (OR 0.87, *P* = 0.06) and male hemizygotes (OR 0.81, P = 0.01) ([Supplementary Tables 14, 16, 17](#SD2){ref-type="supplementary-material"}). Below we discuss this heterogeneity of effect in more detail. Similar but weaker trends were observed for rs1050829 which marks the ancestral lineage on which *G6PD*+202 originated^[@R24]^.

ATP2B4 {#S8}
------

*ATP2B4*, encoding a calcium transporter found in the plasma membrane of erythrocytes, has been identified by genome-wide association study (GWAS) as a malaria resistance locus^[@R26]^. We typed 4 SNPs in this gene which were found to be in LD such that the derived alleles of rs10900585 and rs55868763 were associated with increased risk of severe malaria, while the derived alleles of rs4951074 and rs1541255 were associated with decreased risk ([Table 2](#T2){ref-type="table"}, [Supplementary Tables 8--10 and 18](#SD2){ref-type="supplementary-material"}). When averaged across all African sites, individuals carrying at least one copy of the derived allele of rs10900585 had an odds ratio of 1.32 for severe malaria (*P* = 1.7 × 10^−9^) while individuals homozygous for the derived allele at rs4951074 had an odds ratio of 0.77 (*P*=7.6 × 10^−7^). In both cases the magnitude of genetic effect was similar for cerebral malaria and severe malarial anaemia ([Figure 1](#F1){ref-type="fig"}).

CD40LG {#S9}
------

*CD40LG* is a gene on the X chromosome encoding CD40 ligand that has previously been associated with severe malaria.^[@R27]^ Homozygotes for the derived allele of a SNP in the 5' upstream region (rs3092945) showed reduced risk of severe malaria (OR=0.85, *P* = 1.1 × 10^−6^) with a similar trend of protection both in males (OR=0.90, *P* = 0.01) and in females (OR=0.78*, P* = 8.9 × 10^−5^) when the data were aggregated across sites ([Table 3](#T3){ref-type="table"}). However when sites were analysed individually the results were strikingly different between sites: homozygotes for the derived allele showed significantly reduced risk in of severe malaria in The Gambia but significantly increased risk in Kenya ([Supplementary Table 19](#SD2){ref-type="supplementary-material"}).

Other Loci {#S10}
----------

None of the other loci tested here showed consistent evidence of association with severe malaria in the multi-centre analysis with a significance of P \< 10^−4^. [Supplementary Tables 8--10](#SD2){ref-type="supplementary-material"} and [Supplementary Figure 3](#SD1){ref-type="supplementary-material"} show results for all variants tested, some of which are weak associations that merit further investigation. At the *CD36* locus, heterozygotes for codon variant G1439C tended to have reduced risk of severe malaria (OR 0.67, *P* = 4.2 × 10^−4^). Other weak signals of association (*P* values in the range of 0.05 to 0.001) were observed for *CD36, IL1A* and *IRF1* with severe malaria overall, for *CR1* and *IL4* with cerebral malaria and for *IL20RA* with severe malarial anaemia. While it is clear from these data that many genetic associations reported in the literature might have been false positives as has been observed for other common diseases^[@R28]^, it is undoubtedly also the case that authentic genetic associations might be missed by multi-centre studies if the effect is weak and there is heterogeneity of effect across different study sites.

Epistasis Between Significantly Associated Loci {#S11}
-----------------------------------------------

Epistasis between malaria resistance loci has been reported in previous studies^[@R29],[@R30]^. We therefore tested for pairwise interaction between all SNPs that showed significant associations at the HBB, ABO, G6PD, ATP2B4 and CD40LG loci ([Supplementary Table 20](#SD2){ref-type="supplementary-material"} and [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). This did not reveal any strong evidence of interaction but a marginally significant effect was observed between the ATP2B4 locus (rs10900585) and HbC (rs33930165; *P* =1.3 × 10^−3^) such that the ancestral allele of rs10900585, which is the minor allele in Africa, tends to reverse the protective effect of HbC. This warrants further investigation, since *ATP2B4* is the major erythrocyte calcium channel, and intracellular calcium levels have been noted to affect the clinical phenotype of sickling disorders^[@R31]^.

Heterogeneity of Effect {#S12}
-----------------------

The large sample size of this study allowed us to investigate the heterogeneity of effect of malaria resistance loci in greater detail than has hitherto been possible. When associations with *HBB, ABO, G6PD, ATP2B4* and *CD40L* were broken down by population, and when cerebral malaria and severe malarial anaemia were treated as separate phenotypic entities, various different patterns were observed ([Figure 1](#F1){ref-type="fig"}). The standard approach to genetic association analysis, such as the logistic regression methods used above, uses a fixed-effects model which assumes that true associations should be constant across different studies. However patterns of disease association could potentially vary due to a range of genetic, environmental and biological factors, and by understanding this variation we might gain important scientific insights. We therefore used a Bayesian statistical framework to evaluate different models of genetic association allowing for heterogeneity of effect (see Online Methods and ref^[@R32]^). In essence this approach weighs up the evidence that a genetic effect is fixed or heterogeneous when it is compared across different populations and clinical phenotypes, i.e. cerebral malaria and severe malarial anaemia. Here we allow for two sorts of heterogeneous effect: correlated effects, that are not fixed but tend to behave in a similar way; and independent effects, where there is no tendency to behave in a similar way. We estimated the posterior probability of each model under the *a priori* assumption that all models are equally likely. [Figure 2](#F2){ref-type="fig"} shows the results for specific SNPs in *HBB, ABO, G6PD, ATP2B4* and *CD40L* and [Supplementary Figure 5](#SD1){ref-type="supplementary-material"} shows the results for all SNPs.

For HbS and blood group O there was strong evidence for fixed or correlated effects across different populations and clinical phenotypes ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). HbS confers a remarkably fixed level of protection against cerebral malaria and severe malarial anaemia, with heterozygotes showing 89% reduced risk for both conditions when averaged across sites ([Table 2](#T2){ref-type="table"}). HbC and blood group O are less strongly protective than HbS but they too have very similar effects on cerebral malaria and severe malarial anaemia. There are many different theories about the molecular and cellular mechanisms by which HbS, HbC and blood group O act to protect against malaria.^[@R22],[@R33]--[@R36]^ The fact that these variants protect equally against clinical complications as disparate as coma and severe anaemia implies that they act through some general mechanism, e.g. by suppressing parasite density, rather than through a specific effect on particular pathological processes such as cerebral malaria or severe malarial anaemia.

At the *CD40LG* and *ATP2B4* loci there was evidence for heterogeneity of effect across populations ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). For CD40LG rs3092945, the posterior probability of independent effects in different populations was greater than 90%, whereas the effects on clinical phenotype were relatively constant. In the case of ATP2B4 rs10900585, the posterior probability was more evenly balanced between the various models, with some evidence for both fixed and independent effects in different populations. Heterogeneity of effect across populations might indicate some source of biological variation such as epistasis or gene-environment interactions, or it might be because the SNPs showing association are simply genetic markers showing variable patterns of linkage disequilibrium with true malaria resistance alleles. Variable patterns of linkage disequilibrium are particularly common in Africa, such that authentic genetic associations may fail to replicate in different locations unless the causal variant is directly genotyped, but in the long term this form of population heterogeneity may prove extremely useful in genetic fine-mapping of causal variants.^[@R32],[@R37],[@R38]^

The genetic effects observed for *G6PD* were strikingly different in character from those seen at the *HBB, ABO, ATP2B4* and *CD40LG* loci ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). There was strong heterogeneity of effect across different phenotypes, with more than 80% posterior probability that the *G6PD*+202T allele has independent effects on cerebral malaria and severe malarial anaemia, with relatively little heterogeneity of effect across different populations. Previous studies have concluded that G6PD deficiency is protective against *P. falciparum* although there has been debate about whether the protective effect is confined to female heterozygotes or is also present in male hemizygotes.^[@R4],[@R5],[@R25],[@R39]^ With a much larger sample size than any previous study, these data reveal that male hemizygotes and female homozygotes have increased risk of severe malarial anaemia, whereas male hemizygotes and female heterozygotes have reduced risk of cerebral malaria. If males and females are combined in an additive model, the G6PD+202 T allele confers reduced risk of cerebral malaria (OR 0.91, P= 6.1×10^−3^) but increased risk of severe malarial anaemia (OR 1.19, P=2.6 × 10^−5^) and the overall effect on severe malaria is close to neutral (OR 1.02, P=0.15) ([Table 3](#T3){ref-type="table"}, [Supplementary Tables 13--17](#SD2){ref-type="supplementary-material"}).

Discussion {#S13}
==========

Severe malarial anaemia is a complex pathological entity.^[@R40],[@R41]^ Parasites invade and destroy erythrocytes as they replicate, and the host response to infection also leads to erythrocyte destruction and bone marrow suppression. In the developing world, the anaemia is often aggravated by chronic nutritional deficiency and helminthic infection.^[@R41],[@R42]^ G6PD deficiency and the haemoglobinopathies are interesting examples of a biological trade-off between an inherent tendency to cause anaemia and the potential to protect against anaemia by protecting against malaria. The present study allows us to observe the outcome of this trade-off with greater resolution than has hitherto been possible, showing that the risk of severe malarial anaemia is significantly reduced for HbS heterozygotes, HbC homozygotes and HbC heterozygotes, while for G6PD-deficient male hemizygotes and female homozygotes the risk is significantly increased.

G6PD deficiency has excited much interest among evolutionary biologists because it is so common in the human population and displays such a remarkable diversity of allelic forms throughout the tropics and sub-tropics.^[@R3],[@R6],[@R9],[@R23],[@R39],[@R43]^ The main force for evolutionary selection is widely assumed to be severe malaria due to *P. falciparum* but this is called into question by the present findings which show that G6PD deficiency has little effect on the overall risk of severe malaria. These data do not exclude the possibility that *P. falciparum* has played a role, as the present-day risk of cerebral malaria and severe malarial anaemia malaria may not accurately reflect patterns of disease and fatality caused by *P. falciparum* in the past, particularly before anti-malarial drugs became widely used. However it is necessary to consider the possibility of some other evolutionary driving force and an obvious candidate is *P. vivax*, once regarded as benign but increasingly recognised to cause a significant burden of fatality and severe disease^[@R44]^. In a region of Thailand where both species are endemic, G6PD deficiency has been observed to suppress *P. vivax* more effectively than *P. falciparum* infection^[@R45]^. An important biological difference from *P. falciparum* is that *P. vivax* preferentially infects reticulocytes (i.e. young erythrocytes) which have higher levels of G6PD enzyme activity than older erythrocytes, and it is conceivable that in these circumstances G6PD deficiency might exert a stronger protective effect. The geographic distribution of G6PD deficiency broadly coincides with the transmission range of *P. vivax*, with the notable exception of large parts of sub-Saharan Africa where G6PD deficiency is common but *P. vivax* is absent^[@R43],[@R46]^. It has recently been discovered that chimpanzee and gorillas in Africa carry parasites that are closely related to *P. vivax*^[@R47]^. Evolutionary analysis of these ape parasite lineages indicates that human *P. vivax* is of African origin, suggesting that *P. vivax* may have been common in Africa before the selective sweep of the FY\*O allele (Duffy negative blood group) led to its elimination from most of the continent^[@R48],[@R49]^.

Large multi-centre studies have transformed the field of human genetics over the past decade but there remain significant practical challenges in conducting such studies in the developing world. Obtaining reliable phenotypic data can be difficult in resource-poor settings, particularly for acute conditions such as severe malaria which rely on accurate clinical records at the time of illness. We have endeavoured to overcome these obstacles by establishing systems for standardising and sharing data from research groups in different countries. The extremely strong phenotypic associations observed for sickle cell trait and blood group O, and their remarkably consistent effects on different clinical forms of severe malaria, illustrate the effectiveness of this approach and provide a benchmark for evaluating other loci. A key finding is that most previously reported candidate gene associations fail to replicate, and an important use of the sample collections established by this project will be to discover authentic novel loci by conducting genome-wide association studies (GWAS) on a larger scale than previously possible. A critical consideration when conducting multi-centre GWAS is that true genetic effects can exhibit marked heterogeneity across different populations, and here we propose a statistical framework for dealing with this problem. There are many potential sources of heterogeneity including interactions with other infections and environmental variables. An important source of heterogeneity could be parasite genetic variation, whose impact on the clinical outcome of malaria remains very poorly understood, and this is an area of future investigation which could yield important biological insights. Previously this has been difficult to address in a systematic manner but with growing knowledge about the natural landscape of genome variation in both the host and the parasite there is the potential to discover novel genetic interactions, e.g. between parasite ligands and host receptors for erythrocyte invasion, that could be of great practical importance for vaccine development. This will require a framework for large-scale genetic epidemiology studies, and here we demonstrate the feasibility of integrating data across multiple locations to achieve scientific insights which could not be achieved by individual studies in isolation.

Online Methods {#S14}
==============

Cases of severe malaria were recruited on admission to hospital, usually as part of a larger programme of clinical research on malaria, designed and led by local investigators. A control group was recruited at each of the study sites to match the ethnic composition of the cases ([Supplementary Tables 1,2,4](#SD2){ref-type="supplementary-material"}). The control group was intended to be representative of the general population, and cord blood samples were used as controls at several study sites. We describe elsewhere the details of study design at individual sites and local epidemiological conditions including malaria endemicity (refs^[@R21],[@R50]--[@R53]^ and the MalariaGEN website (see URLs). Following consultation with the Severe Malaria in African Children network and other clinical experts, a standardised case-report form was developed to record the clinical features of severe malaria^[@R14]^ (The case-report form can be found on the MalariaGEN website \[URLs\]). This was not intended to replace local practice but to encourage uniformity in the core data collected across the different sites. A secure web application was developed to enable investigators to upload and curate their data, and to transform it into standardised units and format, before releasing it to the consortial database. A data fellow was appointed at each site with responsibility for the process of integrating local clinical data with the central database. As part of a capacity building program, data fellows received training in data management and analysis. Moreover, ethics advice, support and training/capacity-building in ethics were provided to Data Fellows and partners throughout the life of the study.

The normalised clinical data from each study site were combined to ascertain phenotypes in a standardised manner across the entire data set ([Supplementary Table 21](#SD2){ref-type="supplementary-material"}). A case of severe malaria was defined as an individual admitted to a hospital or clinic with *P. falciparum* parasites in the blood film and with clinical features of severe malaria as defined by WHO criteria^[@R11],[@R12]^. Severe malaria comprises a number of overlapping syndromes, the most commonly reported being cerebral malaria and severe malarial anaemia. In keeping with standard criteria cerebral malaria is defined here as a case of severe malaria with Blantyre Coma Score of \<3 for a child, or a Glasgow Coma Score of \<9 for an adult. Severe malarial anaemia is defined here as a case of severe malaria with a haemoglobin level of \<5g/dl or a haematocrit level of \<15%. In this report we do not attempt to classify other severe malaria syndromes, such as respiratory distress, that are more complicated to standardise among study sites, although they would be present in our data set. Control samples were either collected from cord bloods or if sampled from the local population, were microscopically negative for malaria.

Genotyping {#S15}
----------

We selected the Sequenom^®^ iPLEX Mass-Array platform for genotyping because of its sample high-throughput capacity, adaptability for assay design and ability to genotype up to 40 SNPs in one reaction. We chose to design 2 iPLEX multiplexes as a compromise between maximising the SNPs we could type on any given sample and the time and cost to genotype all the samples submitted to the MalariaGEN Resource Centre for the various projects.

Altogether 89 SNPs were finally designed and tested in 2 rounds of multiplex design on 33,138 samples ([Supplementary Tables 5--7](#SD2){ref-type="supplementary-material"}, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Of these, 16 SNPs were excluded during the multiplex design and testing phase for a number of reasons: 9 were missing data in more than 20% of the samples; 1 showed a mismatch between the published sequence and the human reference genome; 1 was monomorphic; and 5 could not be redesigned into the final multiplexes ([Supplementary Table 7](#SD2){ref-type="supplementary-material"}). Of the remaining 73 SNPs genotyped, 55 were included on the basis of a known genetic association with severe malaria ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}), 3 were used to confirm or type gender and 15 were selected to aid sample quality control ([Supplementary Table 6, Supplementary Note and Supplementary Tables 22--24](#SD2){ref-type="supplementary-material"}). In the quality control phase, one of the 55 SNPs with a known association with severe malaria, rs1800750 (TNF-376), showed a large deviation in Hardy-Weinberg Equilibrium and was removed from further analysis (HWE see Statistical Analysis section below).

Samples {#S16}
-------

A total of 38,926 individual records comprising 16,433 cases of severe malaria and 22,492 controls were obtained from across the 12 study sites ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Clinical data for gender were missing in 4% of records (we confirm or type sample genders by genotyping) and for ethnic group in 2% of records. A total of 33,138 samples were genotyped. Each sample was assessed for inclusion in the analysis if it was successfully genotyped in more than 90% of 65 analysis SNPs (excluding ATP2B4 SNPs): we excluded 789 samples on this basis ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}). The majority of sample failures were found to be due to blood storage and DNA extraction issues. After quality control of both phenotypic and genotypic data, 11,890 severe malaria cases and 17,441 controls were included for analysis ([Table 1](#T1){ref-type="table"}).

There were 213 different ethnic groups of which 41 comprised at least 5% of individuals at a study site; these included Mandinka, Jola, Wollof, Fula (Gambia); Bambara, Malinke, Peulh, Sarakole (Mali); Mossi (Burkina Faso); Akan, Frarra, Nankana, Kasem (Ghana); Yoruba (Nigeria); Bantu, Semi-Bantu (Cameroon); Chonyi, Giriama, Kauma (Kenya); Mzigua, Wasambaa, Wabondei (Tanzania); Chewa (Malawi); Madang, Sepik (Papua New Guinea); Kinh (Viet Nam). For purposes of analysis we classified ethnic groups with very small sample size (less than 5% of individuals at any study site) as 'other' ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}).

Statistical Analysis {#S17}
--------------------

All statistical analyses were performed using the statistical software environment R (see URLs). As part of the genotyping QC process we identified SNPs with large deviations from HWE that might possibly signify assay failure. Overall HWE was assessed from the distribution of HWE P-values calculated for each SNP by country and ethnic group after discarding groups where the calculated allele frequency was less than 5/2N (where N is the number of individuals in the group)^[@R54]^. An assay was marked for potential exclusion if the results deviated from HWE (*P* \< 10^−4^) in more than 4 ethnic groups ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}).

Single SNP tests of association, adjusted for HbS genotype, gender and ethnicity, for association with severe malaria and severe malaria subtypes cerebral malaria only and severe malarial anaemia only were performed for the 55 SNPs with a known association with severe malaria. Standard logistic regression models were used for tests of association at each autosomal SNP ([Supplementary Table 25](#SD2){ref-type="supplementary-material"}). Primary analyses comprised tests of association between each SNP and severe malaria phenotypes across all individuals combined as well as separately by gender (X chromosome SNPs only) and site: genotypic, additive, dominant, recessive and heterozygote advantage genetic models were considered. For X-chromosome SNPs, males were treated as homozygous females. Therefore when analysing the males only for X chromosome SNPs, the genotypic, dominant, recessive and additive models are equivalent and the heterozygous model is redundant: in this case we present the results from the dominant model (referred to as the male hemizygote model for males at X chromosome SNPs) and note that the ORs correspond to the change in the odds of disease for males hemizygous for the derived allele compared to males hemizygous for the ancestral allele. For combined analyses of males and females at X chromosome SNPS, robust estimates of variance were used to account for the unequal variance^[@R55]^ and all models are then appropriate. In secondary analyses we considered additional genetic models comparing effects between homozygotes and heterozygotes at selected SNPs. ORs and 95% confidence intervals were derived from Wald tests applied to regression coefficients. Significance was assessed using likelihood ratio tests of association except for combined analyses of males and females at X chromosome SNPs where Wald tests were applied using the robust variance estimates. Results are presented with respect to the association between the derived (non-ancestral allele) and the severe malaria phenotype in question.

The standard logistic regression analyses assume that effects are fixed across all sites. In order to investigate evidence for genetic heterogeneity across severe malaria subtypes both within and across African sites, we compared different models of association in a Bayesian statistical framework. The models we considered comprised fixed, independent or correlated effects between subtypes within a site crossed with fixed, independent or correlated effects of each subtype across all sites. See [Supplementary Information](#SD2){ref-type="supplementary-material"} for more details. For each SNP we assumed a normally distributed prior on the log odds ratio of association with mean zero and standard deviation σ where σ = 1 for rs334 to reflect the prior believe that the effect size is large consistent with the observed ORs of approximately 0.1; σ = 0.4 for SNPs found to be significant in fixed-effect analyse and; σ = 0.2 otherwise. To model fixed, independent or correlated effects either within or across sites, we set correlation parameters between subtypes to 1, 0.1 and 0.96 respectively. Multinomial regression was used to make independent maximum likelihood estimates of the effect of each SNP on these mutually exclusive subtypes for all individuals combined at each African site. Estimates were adjusted for sex, ethnicity and, with the exception of rs334, sickle-cell trait. Approximate Bayes Factors (ABFs) were then calculated for each SNP and model and used to estimate a posterior probability of each of the models for each SNP.

We also tested for interaction between all pairs of SNPs that were significant in the single SNP analysis; 25 pairs of markers were tested ([Supplementary Table 20](#SD2){ref-type="supplementary-material"}). We considered two different statistical models of interaction: (1) A 1 degree of freedom (df) "Best Model" test for the optimal genetic model for each SNP (as defined by association with SM for all individuals across all sites in a fixed effect model adjusted for ethnicity and gender) at each of the interacting loci; (2) A more general "Genotype" test using a model which allows for separate effects for heterozygous and homozygous genotypes at each of the interacting loci. At X chromosome SNPs, male individuals were treated as homozygous females and only additive effects were considered. For a pair of autosomal SNPs, the Genotype test is then a 4 degree of freedom (df) test of interaction; for a pair comprising an autosomal and an X chromosome SNP, it is a 3 df test and for a pair of X chromosome SNPs, a 1df test. Tests of interaction were performed by testing whether the regression coefficients that represent interaction terms in the corresponding logistic regression model were equal to zero or not. These tests are described in more detail in Cordell^[@R56]^.
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![Forest plots for association with severe malaria and sub phenotypes\
Odds ratios and 95% confidence intervals (CI) are shown for Sickle-cell trait (rs334, heterozygote model), Blood group O (rs8176719, recessive model), ATP2B4 (rs10900585, dominant model), G6PD deficiency (rs1050828, additive model) and (e) CD40LG (rs3092945, recessive model) for association with cerebral malaria (lines with red dots) and severe malarial anaemia (lines with blue dots) in all individuals combined. Results are adjusted for gender, ethnicity and (with the exception of rs334) for sickle cell trait. Results are not presented when the sample size is too small (fewer than 5 cases or controls with relevant genotype) or for locations where the derived allele is absent. Further details are available in [Supplementary Tables 11--19](#SD2){ref-type="supplementary-material"}. The OR=1 for no effect is highlighted by the vertical dashed line.](nihms626188f1){#F1}

![Genetic heterogeneity of severe malaria subtypes cerebral malaria only and severe malarial anaemia only within and across African sites for significant loci\
Bar plots show the distribution of probability between each of nine models of association where the effects on each phenotype are fixed, independent or correlated *within* a site combined with being fixed independent or correlated across all sites (see legend). Models are *a priori* assumed to be equally likely (See [Online Methods and Supplementary Note](#SD2){ref-type="supplementary-material"} for details). Results are shown for SNPs rs334 (HbS, heterozygote model) in HBB, rs8176719 homozygotes (Blood Group O) in ABO, rs10900585 in ATP2B4, G6PD+202 (rs1050828) in G6PD and rs3092945 in CD40LG.](nihms626188f2){#F2}

###### 

Clinical phenotype case counts and percentage of case fatalities.

                     Cases           Controls                                                 
  ------------------ --------------- -------------- ------------- ------------- ------------- -----------
  Gambia             2425 (14)       785 (26)       458 (4)       126 (26)      1056 (6)      3342
  Mali               453 (14)        86 (26)        185 (8)       74 (20)       108 (25)      344
  Burkina Faso       865 (5)         107 (20)       399 (10)      20 (20)       339 (4)       729
  Ghana (Navrongo)   682 (4)         22 (27)        248 (2)       14 (36)       398 (3)       489
  Ghana (Kumasi)     1496 (4)        230 (10)       551 (2)       75 (13)       640 (2)       2042
  Nigeria            77 (4)          6 (17)         8 (12)        0 (0)         63 (2)        40
  Cameroon           621 (5)         39 (19)        82 (7)        8 (50)        492 (4)       578
  Kenya              2268 (11)       909 (14)       160 (8)       214 (16)      985 (7)       3949
  Tanzania           429 (11)        34 (41)        182 (4)       28 (29)       185 (11)      453
  Malawi             1388 (17)       873 (15)       132 (7)       166 (19)      217 (2)       2697
  Vietnam            794 (11)        211 (18)       31 (6)        8 (12)        544 (9)       2538
  Papua New Guinea   392 (2)         43 (5)         120 (2)       9 (11)        220 (0)       240
                                                                                              
  **Total**          **11890(10)**   **3345(18)**   **2196(4)**   **742(20)**   **5607(5)**   **17441**

Numbers are given for cases of all-severe-malaria by study site with percentage of case-fatalities in brackets. Cases are further divided into those with cerebral malaria only, severe malarial anaemia only, both cerebral malaria and severe malarial anaemia and other severe malaria.

###### 

Autosomal single nucleotide polymorphisms (SNPs) with strong association signals.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene\        Alleles\     Frequency of the Derived Allele\   Case\                  Frequency of the Derived Allele in\   Model[a](#TFN5){ref-type="table-fn"}   Model\       Model\             
  SNP          Ancestral\   in Controls\                       Phenotype              Cases\                                                                       OR(95% CI)   *P*                
               /Derived     (Ancestral Hom/Het/\                                      (Ancestral Hom/Het/\                                                                                         
                            Derived Hom)                                              Derived Hom)                                                                                                 
  ------------ ------------ ---------------------------------- ---------------------- ------------------------------------- -------------------------------------- ------------ ------------------ -----------------
  **ABO**      rs8176719    I/D                                0.69(1700/7215/8238)   Severe malaria                        0.64(1506/5533/4750)                   R            0.74(0.7--0.78)    4.99 × 10^−33^

                                                                                      Cerebral malaria only                 0.64(415/1537/1373)                    R            0.73(0.67--0.79)   8.85 × 10^−16^

                                                                                      Severe malarial anaemia only          0.62(302/1054/816)                     R            0.68(0.62--0.76)   7.97 × 10^−14^

               rs8176746    C/A                                0.17(11943/4852/565)   Severe malaria                        0.2(7512/3817/507)                     D            1.25(1.19--1.32)   2.01 × 10^−17^

                                                                                      Cerebral malaria only                 0.2(2148/1049/138)                     A            1.27(1.18--1.36)   2.00 × 10^−11^

                                                                                      Severe malarial anaemia only          0.22(1342/746/97)                      D            1.28(1.16--1.42)   1.71 × 10^−06^

                                                                                                                                                                                                   

  **ATP2B4**   rs10900585   G/T                                0.66(1644/5722/5737)   Severe malaria                        0.68(868/4056/4203)                    D            1.32(1.21--1.45)   1.69 × 10^−09^

                                                                                      Cerebral malaria only                 0.69(245/1168/1236)                    D            1.35(1.17--1.57)   3.06 × 10^−05^

                                                                                      Severe malarial anaemia only          0.69(159/816/851)                      D            1.53(1.27--1.84)   3.68 × 10^−06^

               rs1541255    A/G                                0.32(6241/5667/1439)   Severe malaria                        0.29(4558/3922/743)                    R            0.75(0.68--0.83)   4.87 × 10^−09^

                                                                                      Cerebral malaria only                 0.29(1334/1122/200)                    R            0.7(0.59--0.82)    4.03 × 10^−06^

                                                                                      Severe malarial anaemia only          0.29(932/788/137)                      R            0.67(0.55--0.82)   3.96 × 10^−05^

                                                                                                                                                                                                   

  **HBB**      rs334        A/T                                0.07(12773/1791/77)    Severe malaria                        0.02(10388/213/84)                     H            0.14(0.12--0.16)   1.62 × 10^−225^

                                                                                      Cerebral malaria only                 0.01(3041/42/5)                        H            0.11(0.08--0.15)   4.67 × 10^−88^

                                                                                      Severe malarial anaemia only          0.03(1965/31/45)                       H            0.11(0.07--0.15)   9.25 × 10^−65^

               rs33930165   G/A                                0.03(9341/515/74)      Severe malaria                        0.04(6866/445/46)                      A            0.71(0.63--0.8)    6.87 × 10^−09^

                                                                                      Cerebral malaria only                 0.02(1412/56/5)                        A            0.72(0.56--0.94)   0.01

                                                                                      Severe malarial anaemia only          0.04(1465/116/10)                      A            0.74(0.6--0.9)     2.11 × 10^−03^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Odds Ratios (OR), 95% Confidence Intervals (95% CI) and *P*-values (*P*) for the optimal genotypic model (Model) are presented for males and females combined. Results are adjusted for gender, ethnicity and (with the exception of rs334) for sickle cell trait. Study sites at which a SNP was monomorphic were excluded from analysis. Further models are shown in [Tables S8--S10 and S11--S13](#SD2){ref-type="supplementary-material"}.

Association P-values for all SNPs can be found in [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}.

Hom, Homozygote; Het, Heterozygote;

Models are A, Additive; D, Dominant; H Heterozygote Advantage; R, Recessive.

###### 

X-chromosome single nucleotide polymorphisms (SNPs) with strong association signals.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene         SNP         Alleles\     Sample   Frequency of the Derived\   Case\                          Frequency of the Derived Allele in\   Model[a](#TFN9){ref-type="table-fn"}   Model\             Model\
                           Ancestral\            Allele in\                  Phenotype                      Cases\                                                                       OR(95% CI)         *P*
                           /Derived              Controls\                                                  (Ancestral Hom/Het/\                                                                            
                                                 (Ancestral Hom/Het/\                                       Derived Hom)                                                                                    
                                                 Derived Hom)                                                                                                                                               
  ------------ ----------- ------------ -------- --------------------------- ------------------------------ ------------------------------------- -------------------------------------- ------------------ ----------------
  **CD40LG**   rs3092945   T/C          All      0.27(11030/2621/3197)       Severe malaria                 0.29(7123/2035/2250)                  R                                      0.85(0.79--0.91)   1.11 × 10^−06^

                                                                             Cerebral malaria only          0.27(2102/576/596)                    R                                      0.85(0.76--0.94)   2.45 × 10^−03^

                                                                             Severe malarial anaemia only   0.32(1197/411/452)                    R                                      0.82(0.73--0.94)   2.97 × 10^−03^

                                        F        0.27(4581/2621/849)         Severe malaria                 0.3(2636/2035/513)                    R                                      0.78(0.69--0.88)   8.93 × 10^−05^

                                                                             Cerebral malaria only          0.29(813/576/157)                     R                                      0.9(0.74--1.09)    0.27

                                                                             Severe malarial anaemia only   0.33(424/411/103)                     R                                      0.71(0.56--0.9)    3.49 × 10^−03^

                                        M        0.27(6449/0/2348)           Severe malaria                 0.28(4487/0/1737)                     M                                      0.9(0.83--0.98)    0.01

                                                                             Cerebral malaria only          0.25(1289/0/439)                      M                                      0.85(0.75--0.97)   0.01

                                                                             Severe malarial anaemia only   0.31(773/0/349)                       M                                      0.87(0.75--1.01)   0.07

                                                                                                                                                                                                            

  **G6PD**     rs1050828   C/T          All      0.15(11552/1770/1279)       Severe malaria                 0.15(8516/1152/1000)                  A                                      1.02(0.97--1.06)   0.15

                                                                             Cerebral malaria only          0.13(2513/338/230)                    A                                      0.91(0.85--0.97)   6.08 × 10^−03^

                                                                             Severe malarial anaemia only   0.18(1563/215/263)                    A                                      1.19(1.1--1.28)    2.62 × 10^−05^

                                        F        0.15(5069/1770/174)         Severe malaria                 0.14(3705/1152/134)                   A                                      0.95(0.88--1.03)   0.23

                                                                                                                                                  R                                      1.15(0.9--1.46)    0.27

                                                                                                                                                  H                                      0.9(0.82--0.99)    0.02

                                                                             Cerebral malaria only          0.14(1129/338/39)                     A                                      0.92(0.82--1.04)   0.19

                                                                                                                                                  R                                      1.09(0.76--1.57)   0.65

                                                                                                                                                  H                                      0.87(0.76--1.01)   0.06

                                                                             Severe malarial anaemia only   0.16(669/215/41)                      A                                      1.12(0.96--1.3)    0.15

                                                                                                                                                  R                                      1.94(1.3--2.89)    1.92 × 10^−03^

                                                                                                                                                  H                                      0.93(0.77--1.11)   0.42

                                        M        0.15(6483/0/1105)           Severe malaria                 0.15(4811/0/866)                      M                                      1.1(0.99--1.22)    0.07

                                                                             Cerebral malaria only          0.12(1384/0/191)                      M                                      0.81(0.68--0.96)   0.01

                                                                             Severe malarial anaemia only   0.2(894/0/222)                        M                                      1.49(1.24--1.79)   3.55 × 10^−05^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Odds Ratios (OR), 95% Confidence Intervals (95% CI) and *P*-values (*P*) for the optimal genetic model (Model). Results are adjusted for gender (all individuals combined), ethnicity and sickle cell trait.. Study sites at which a SNP was monomorphic were excluded from analysis. Further models are shown in Tables S8--S10 and S14 --S17.

Association P-values for all SNPs can be found in [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}.

Hom, Homozygote; Het, Heterozygote.

Models are A, Additive; D, Dominant; H Heterozygote Advantage; M, Male Hemizygote; R, Recessive.

[^1]: A full list of authors appears at the end of this article. Full contribution is listed in [Supplementary Note](#SD2){ref-type="supplementary-material"}.
